Last 48 quarters of trend data · Healthcare · Medical - Healthcare Information Services
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Omnicell, Inc.'s quarterly P/E stands at 33.4x. EV/EBITDA has compressed 73.7% YoY to 10.5x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 881.49 | 33.38 | — | 63.44 | 61.25 | — | 32.74 | 57.37 | 83.45 | — | — | 93.83 | 242.65 |
| — | — | — | +10.6% | -26.6% | — | — | -38.9% | -65.6% | — | — | +59.6% | +70.7% | |
| P/S Ratio | 1.50 | 1.24 | 1.62 | 1.14 | 1.18 | 1.51 | 1.68 | 1.79 | 1.13 | 1.36 | 1.65 | 1.72 | 2.80 |
| — | -18.1% | -3.3% | -36.2% | +4.9% | +11.2% | +1.5% | +4.2% | -59.8% | -40.1% | -12.6% | -40.0% | -29.4% | |
| P/B Ratio | 1.47 | 1.22 | 1.65 | 1.16 | 1.09 | 1.30 | 1.66 | 1.64 | 1.04 | 1.12 | 1.44 | 1.73 | 2.88 |
| — | -5.8% | -0.2% | -29.2% | +4.9% | +15.2% | +15.0% | -4.9% | -64.0% | -51.2% | -27.8% | -50.8% | -40.2% | |
| P/FCF | 20.44 | 9.11 | 25.19 | 19.18 | 11.08 | 27.61 | 10.90 | 53.73 | 6.90 | 8.88 | 16.43 | 11.07 | 13.67 |
| — | -67.0% | +131.1% | -64.3% | +60.6% | +210.7% | -33.7% | +385.4% | -49.5% | -96.5% | +99.8% | -90.7% | — | |
| EV / EBITDA | 21.25 | 10.48 | 25.27 | 13.09 | 12.25 | 39.82 | 14.40 | 17.99 | 12.53 | 80.01 | 1293.94 | 20.35 | 28.02 |
| — | -73.7% | +75.5% | -27.2% | -2.2% | -50.2% | -98.9% | -11.6% | -55.3% | -86.1% | — | -19.0% | -24.7% | |
| EV / EBIT | 345.68 | 22.03 | 519.96 | 32.42 | 32.48 | — | 20.97 | 40.49 | 101.18 | — | — | 149.45 | 115.03 |
| — | — | +2379.8% | -19.9% | -67.9% | — | — | -72.9% | -12.0% | — | — | +154.4% | +1.9% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Omnicell, Inc.'s operating margin was 5.4% in Q1 2026, up 5.3 pp QoQ and up 9.7 pp YoY. The trailing four-quarter average of 2.8% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 10.1% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 42.5% | 45.3% | 41.5% | 43.3% | 43.9% | 41.1% | 46.6% | 43.5% | 41.3% | 38.7% | 40.7% | 44.2% | 45.0% |
| — | +10.1% | -10.9% | -0.5% | +6.4% | +6.2% | +14.4% | -1.5% | -8.1% | -10.0% | -0.4% | -3.3% | -5.7% | |
| Operating Margin | 0.4% | 5.4% | 0.1% | 2.7% | 2.8% | -4.3% | 4.5% | 2.5% | 1.2% | -7.6% | -9.0% | 1.2% | 2.6% |
| — | +226.2% | -97.1% | +4.3% | +139.9% | +43.2% | +149.7% | +104.7% | -55.1% | +3.9% | +29.9% | -76.6% | -31.2% | |
| Net Margin | 0.2% | 3.7% | -0.6% | 1.8% | 1.9% | -2.6% | 5.2% | 3.1% | 1.3% | -6.4% | -5.6% | 1.9% | 1.2% |
| — | +240.7% | -112.5% | -42.5% | +43.8% | +59.1% | +193.0% | +64.3% | +16.9% | -23.4% | +41.8% | -61.4% | -57.8% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 0.2% | 0.9% | -0.2% | 0.4% | 0.4% | -0.6% | 1.3% | 0.7% | 0.3% | -1.3% | -1.2% | 0.5% | 0.3% |
| — | +262.5% | -112.9% | -38.0% | +43.2% | +57.4% | +205.8% | +50.1% | +4.4% | +0.1% | +51.8% | -68.6% | -64.2% | |
| ROA | 0.1% | 0.6% | -0.1% | 0.3% | 0.3% | -0.3% | 0.7% | 0.4% | 0.2% | -0.7% | -0.6% | 0.3% | 0.2% |
| — | +273.6% | -114.4% | -29.0% | +60.7% | +52.7% | +210.8% | +49.3% | +5.2% | -3.4% | +50.1% | -67.7% | -63.6% | |
| ROIC | 0.3% | 1.0% | 0.0% | 0.5% | 0.5% | -0.7% | 0.8% | 0.4% | 0.2% | -1.1% | -1.3% | 0.2% | 0.4% |
| — | +248.9% | -96.9% | +16.6% | +156.7% | +35.0% | +162.6% | +108.5% | -54.4% | +12.2% | +34.2% | -78.3% | -35.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Omnicell, Inc.'s Debt/EBITDA ratio is 5.4x, down from 10.1x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 8.2% YoY to 1.50x, strengthening the short-term liquidity position. Debt/Equity has declined for 5 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.15 | 0.17 | 0.17 | 0.30 | 0.31 | 0.31 | 0.50 | 0.51 | 0.52 | 0.52 | 0.52 | 0.53 |
| — | -50.6% | -46.1% | -66.0% | -40.5% | -40.7% | -40.4% | -3.3% | -3.1% | -3.8% | -5.4% | -5.3% | -7.0% | |
| Debt / EBITDA | 2.43 | 5.38 | 10.10 | 7.48 | 13.87 | 37.74 | 10.63 | 21.37 | 23.64 | 136.82 | 1710.56 | 22.46 | 19.32 |
| — | -85.7% | -5.0% | -65.0% | -41.3% | -72.4% | -99.4% | -4.8% | +22.3% | -72.0% | — | +56.9% | +18.0% | |
| Current Ratio | 1.43 | 1.50 | 1.43 | 1.44 | 1.42 | 1.38 | 1.37 | 1.05 | 2.45 | 2.38 | 2.52 | 2.47 | 2.38 |
| — | +8.2% | +4.2% | +37.4% | -41.9% | -41.9% | -45.7% | -57.5% | +2.7% | +15.4% | +22.5% | +9.7% | +12.9% | |
| Quick Ratio | 1.22 | 1.29 | 1.22 | 1.21 | 1.24 | 1.23 | 1.22 | 0.95 | 2.22 | 2.13 | 2.22 | 2.16 | 2.03 |
| — | +4.7% | -0.4% | +26.9% | -43.9% | -42.1% | -45.1% | -55.9% | +9.3% | +21.8% | +29.7% | +15.9% | +18.9% | |
| Interest Coverage | 2.84 | 330.47 | 3.46 | 7.65 | 29.95 | -33.48 | 22.22 | 11.21 | 2.84 | -14.70 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OMCL stock.
Omnicell, Inc.'s current P/E is 881.5x. The average P/E over the last 3 quarters is 52.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Omnicell, Inc.'s current operating margin is 0.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Omnicell, Inc.'s business trajectory between earnings reports.